Zhejiang Ausun Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2023: USD 31.25 M

Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Cash Flow is USD 31.25 M for the year ending December 31, 2023, a 78.85% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2022 was USD 17.47 M, a -36.16% change year over year.
Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2021 was USD 27.37 M, a 29.01% change year over year.
Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2020 was USD 21.21 M, a 68.39% change year over year.
Zhejiang Ausun Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2019 was USD 12.60 M, a 653.19% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Shanghai Stock Exchange: 603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd.

CEO	Mr. Zhiguo Zheng
IPO Date	May 9, 2017
Location	China
Headquarters	No. 5 Donghai Fourth Lane
Employees	1,174
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials

Description

Zhejiang Ausun Pharmaceutical Co., Ltd. develops, produces, and sells specialty drug substances and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it is involved in the processing, and research and development business. The company was founded in 2010 is based in Linhai, China.

Key trends

Past 5 years